Tag Archives: cannabis

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

Posted on by

“…exogenous CB1agonists can provide significant neuroprotection from the consequences of inflammatory CNS disease… Therefore, in addition to symptom management, cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other diseases.

The results of this study are important because they suggest that in addition to symptom management, cannabinoids offer the potential to slow the progression of a disease that as yet has no satisfactory treatment.”

http://brain.oxfordjournals.org/content/126/10/2191.full

Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Posted on by

“Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain) (Level A). Clinicians might offer tetrahydrocannabinol for spasticity symptoms and pain (excluding central neuropathic pain) (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity (short-term)/tremor (Level B) and possibly effective for spasticity and pain (long-term) (Level C). Clinicians might offer Sativex oromucosal cannabinoid spray (nabiximols) for spasticity symptoms, pain, and urinary frequency (Level B). Clinicians should counsel patients that these agents are probably ineffective for objective spasticity/urinary incontinence (Level B). Clinicians might choose not to offer these agents for tremor (Level C). Clinicians might counsel patients that magnetic therapy is probably effective for fatigue and probably ineffective for depression (Level B); fish oil is probably ineffective for relapses, disability, fatigue, MRI lesions, and quality of life (QOL) (Level B); ginkgo biloba is ineffective for cognition (Level A) and possibly effective for fatigue (Level C); reflexology is possibly effective for paresthesia (Level C); Cari Loder regimen is possibly ineffective for disability, symptoms, depression, and fatigue (Level C); and bee sting therapy is possibly ineffective for relapses, disability, fatigue, lesion burden/volume, and health-related QOL (Level C)…”

http://www.ncbi.nlm.nih.gov/pubmed/24663230

AAN calls oral cannabinoids effective for MS pain, spasticity

Posted on by

“An expert panel organized by the American Academy of Neurology called oral cannabis extract the only complementary and alternative medicine unequivocally effective for helping patients with multiple sclerosis, specifically easing their pain and symptoms of spasticity, medicine possibly for as long as 1 year of treatment.”

http://www.clinicalpsychiatrynews.com/cme/click-for-credit-articles/single-article/aan-calls-oral-cannabinoids-effective-for-ms-pain-spasticity/6ca42663d197581d76107390a304ec4d.html

Study: Marijuana only alternative therapy showing promise for MS patients

Posted on by

MarijuanaGrow-Medicinal

“Researchers said medical marijuana seems to be the only “alternative therapy” showing promise for helping those with multiple sclerosis.

Officials at Oregon Health and Science University said research shows therapies like massage and acupuncture aren’t as effective as medical marijuana.”

http://kfor.com/2014/03/24/study-marijuana-only-alternative-therapy-showing-promise-for-ms-patients-massage-acupuncture-dont/

Neurologists Say Medical Marijuana Effective in Treating MS

Posted on by

Image courtesy of GW Pharmaceuticals

“The American Academy of Neurology has become one of the first medical organizations in the U.S. to endorse the use of medical marijuana.

In new guidelines published in the journal Neurology, the Academy said oral cannabis, medical marijuana pills and medical marijuana spray may help ease symptoms of muscle spasticity and frequent urination caused by multiple sclerosis (MS).”

http://americannewsreport.com/nationalpainreport/neurologists-say-medical-marijuana-effective-treating-ms-8823383.html

Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis

Posted on by

“Controlled trial shows improved spasticity, reduced pain after smoking medical marijuana

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity – a common and disabling symptom of this neurological disease.”

http://health.ucsd.edu/news/releases/Pages/2012-05-14-smoked-cannabis-reduces-symptoms-of-multiple-sclerosis.aspx

Medical marijuana

“Medical marijuana eases some MS symptoms, neurologists report” http://www.latimes.com/science/sciencenow/la-sci-sn-treating-ms-with-cannabis-20140324,0,2596095.story

Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.

Posted on by

“Delta(9)-Tetrahydrocannabinol (Delta(9)-THC), the major psychoactive constituent of Cannabis sativa L., has been widely studied for its potential pharmaceutical application in the treatment of various diseases and disturbs.

The aim of this work was to develop a stable aqueous Delta(9)-THC formulation acceptable for different ways of administration, and to evaluate the therapeutic properties of the new Delta(9)-THC based preparation for pain treatment.

Significant antinociceptive activity has been detected by both intraperitoneal and intragastric administration of the new Delta(9)-THC pharmaceutical preparation.”

http://www.ncbi.nlm.nih.gov/pubmed/20399844

Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System

Posted on by

An external file that holds a picture, illustration, etc. Object name is pone.0089566.g002.jpg

“The “classic” endocannabinoid (eCB) system… An emerging literature documents the “eCB deficiency syndrome” as an etiology in migraine, fibromyalgia, irritable bowel syndrome, psychological disorders, and other conditions. We performed a systematic review of clinical interventions that enhance the eCB system—ways to upregulate cannabinoid receptors, increase ligand synthesis, or inhibit ligand degradation.

Evidence indicates that several classes of pharmaceuticals upregulate the eCB system, including analgesics (acetaminophen, non-steroidal anti-inflammatory drugs, opioids, glucocorticoids), antidepressants, antipsychotics, anxiolytics, and anticonvulsants.

Clinical interventions characterized as “complementary and alternative medicine” also upregulate the eCB system: massage and manipulation, acupuncture, dietary supplements, and herbal medicines. Lifestyle modification (diet, weight control, exercise, and the use of psychoactive substances—alcohol, tobacco, coffee, cannabis) also modulate the eCB system.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951193/#!po=4.79452

 

“Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Migraine, fibromyalgia, IBS and related conditions display common clinical, biochemical and pathophysiological patterns that suggest an underlying clinical endocannabinoid deficiency that may be suitably treated with cannabinoid medicines.”

 http://www.ncbi.nlm.nih.gov/pubmed/18404144

The draft genome and transcriptome of Cannabis sativa

Posted on by

“Cannabis sativa has been cultivated throughout human history as a source of fiber, oil and food, and for its medicinal and intoxicating properties.

The availability of the Cannabis sativa genome enables the study of a multifunctional plant that occupies a unique role in human culture. Its availability will aid the development of therapeutic marijuana strains with tailored cannabinoid profiles and provide a basis for the breeding of hemp with improved agronomic characteristics.”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359589/